Skip to main content

Table 1 Baseline characteristics of men, comparison by enrolment status and study arm

From: Using surrogate vaccines to assess feasibility and acceptability of future HIV vaccine trials in men: a randomised trial in inner-city Johannesburg, South Africa

Variable Enrolled   Not enrolled (C) (n = 134) P
(A + B vs C)
Immediate (A) (n = 75) Deferred (B) (n = 75) P
(A vs B)
Median age (IQR) 25 (23–29) 26 (23–29) 0.390 30 (26–36) <0.001
Born in SA 50 (66.7) 49 (65.3) 0.864 93 (69.4) 0.541
Single 64 (85.3) 64 (85.3) 1.000 102 (76.1) 0.002
Any employmenta 40 (53.3) 40 (53.3) 1.000 78 (58.2) 0.409
Completed secondary education 72 (96.0) 63 (84.0) 0.018 115 (85.8) 0.482
Johannesburg resident >1 year 69 (92.0) 67 (89.3) 0.575 120 (89.6) 0.530
Median lifetime partners (IQR) 7 (5–13) 9 (5–20) 0.238 10 (6–20) 0.007
Median age coital debut (IQR) 16 (15–18) 16 (15–19) 0.861 17 (15–19) 0.132
Used condom at each sex actb 47 (62.7) 58 (77.3) 0.063 45 (52.3) 0.052
High-risk female partnersc 33 (44.0) 31 (41.3) 0.741 62 (51.7) 0.767
Vaccination historyd 48 (64.0) 55 (73.3) 0.309 106 (79.1) 0.126
Perceived HIV risk 10 (13.3) 6 (8.0) 0.551 32 (23.9) 0.010
Previous sex with male partner 2 (2.7) 1 (1.3) 0.500 4 (3.0) 0.710
Circumcised 22 (29.3) 27 (36.0) 0.384 48 (35.8) 0.545
Syphilise 2 (2.7) 2 (2.7) 0.690 16 (11.9) <0.001
N. gonorrhoea e 2 (2.7) 1 (1.3) 0.500 2 (1.5) 0.553
T. vaginalis e 1 (1.3) 0 (0.0) - 6 (4.5) 0.055
C. trachomatis 10 (6.7) 12 (8.0) 0.907 12 (9.0) 0.139
HSV-2 17 (22.7) 19 (25.3) 0.512 54 (41.2) <0.001
HIV-1 0 (0.0) 0 (0.0) - 16 (12.0) -
Hepatitis B 0 (0.0) 0 (0.0) - 87 (65) -
HIV and hepatitis co-infection 0 (0.0) 0 (0.0) - 10 (7) -
  1. aPart-time, self- or full-employment; bIn past 3 months, with most recent partner; cSex partner has other partners and never tested for HIV to man’s knowledge; dAny vaccination, including experimental or immunisations. eFisher’s exact test